Short Bowel Syndrome – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Short Bowel Syndrome – Pipeline Review, H1 2020’, provides an overview of the Short Bowel Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Short Bowel Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome

– The report reviews pipeline therapeutics for Short Bowel Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Short Bowel Syndrome therapeutics and enlists all their major and minor projects

– The report assesses Short Bowel Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Short Bowel Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Short Bowel Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Short Bowel Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

9 Meters Biopharma Inc

enGene Inc

Hanmi Pharmaceuticals Co Ltd

Huons Global Co Ltd

Micelle BioPharma Inc

OPKO Health Inc

PhaseBio Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Tasly Pharmaceutical Group Co Ltd

VectivBio Holding AG

Worphmed Srl

Zealand Pharma AS

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Short Bowel Syndrome - Overview

Short Bowel Syndrome - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Short Bowel Syndrome - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Short Bowel Syndrome - Companies Involved in Therapeutics Development

9 Meters Biopharma Inc

enGene Inc

Hanmi Pharmaceuticals Co Ltd

Huons Global Co Ltd

Micelle BioPharma Inc

OPKO Health Inc

PhaseBio Pharmaceuticals Inc

Takeda Pharmaceutical Co Ltd

Tasly Pharmaceutical Group Co Ltd

VectivBio Holding AG

Worphmed Srl

Zealand Pharma AS

Short Bowel Syndrome - Drug Profiles

apraglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

exenatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein to Agonize GLP2R for Short Bowel Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy for Short Bowel Syndrome - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

glepaglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GXG-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HL-06 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HM-15912 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melatonin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOD-1501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NB-1002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SC-403 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

teduglutide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZP-7570 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Short Bowel Syndrome - Dormant Projects

Short Bowel Syndrome - Discontinued Products

Short Bowel Syndrome - Product Development Milestones

Featured News & Press Releases

Feb 10, 2020: The Scottish Medicines Consortium advises on newly licensed medicine Revestive for use by NHSScotland

Jun 26, 2019: Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome

May 17, 2019: Therachon to present data from ongoing Phase II Study of Apraglutide for Short Bowel Syndrome at Digestive Disease Week

May 17, 2019: U.S. FDA approves GATTEX (teduglutide) for children 1 year of age and older with Short Bowel Syndrome

May 07, 2019: Zealand Pharma enrolls first patient in Phase 3 extension study of glepaglutide for treatment for short bowel syndrome

May 03, 2019: Hanmi's short bowel syndrome treatment becomes orphan drug in US

Mar 25, 2019: Therachon presents data from preclinical and phase I clinical studies of Apraglutide for the treatment of Short Bowel Syndrome at ASPEN 2019 Nutrition Science & Practice Conference

Feb 05, 2019: Pharm-Olam enrolls patients in Zealand Pharma orphan drug study

Jan 16, 2019: Therachon is granted Orphan Drug Designation by US FDA for Apraglutide for the treatment of Short Bowel Syndrome

Nov 29, 2018: Therachon is granted Orphan Drug Designation in the European Union for apraglutide for the treatment of short bowel syndrome

Nov 13, 2018: U.S. FDA accepts for filing Shire's supplemental New Drug Application for GATTEX (teduglutide [rDNA origin]) for children with Short Bowel Syndrome

Oct 05, 2018: Zealand Pharma enrols first patient in Phase lll study of glepaglutide

May 31, 2018: Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.

Apr 26, 2018: Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome

Apr 09, 2018: Revestive is accepted for restricted use within NHS Scotland

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Short Bowel Syndrome, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Short Bowel Syndrome – Pipeline by 9 Meters Biopharma Inc, H1 2020

Short Bowel Syndrome – Pipeline by enGene Inc, H1 2020

Short Bowel Syndrome – Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2020

Short Bowel Syndrome – Pipeline by Huons Global Co Ltd, H1 2020

Short Bowel Syndrome – Pipeline by Micelle BioPharma Inc, H1 2020

Short Bowel Syndrome – Pipeline by OPKO Health Inc, H1 2020

Short Bowel Syndrome – Pipeline by PhaseBio Pharmaceuticals Inc, H1 2020

Short Bowel Syndrome – Pipeline by Takeda Pharmaceutical Co Ltd, H1 2020

Short Bowel Syndrome – Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2020

Short Bowel Syndrome – Pipeline by VectivBio Holding AG, H1 2020

Short Bowel Syndrome – Pipeline by Worphmed Srl, H1 2020

Short Bowel Syndrome – Pipeline by Zealand Pharma AS, H1 2020

Short Bowel Syndrome – Dormant Projects, H1 2020

Short Bowel Syndrome – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Short Bowel Syndrome, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports